Evidence map›Paper›PMID 35224491›Full record

ArticleBrain communications2022

Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain.

Alexander G Thompson, Elizabeth Gray, Nick Verber, Yoana Bobeva, Vittoria Lombardi, Stephanie R Shepheard, Ozlem Yildiz, Emily Feneberg, Lucy Farrimond, Thanuja Dharmadasa and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Drug repurposing in amyotrophic lateral sclerosis (ALS).Expert opinion on drug discovery · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Alexander G ThompsonNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-1063-3277
Elizabeth GrayNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Nick VerberSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Yoana BobevaBlizard Institute, Queen Mary University of London, London, UK.
Vittoria LombardiBlizard Institute, Queen Mary University of London, London, UK.
Stephanie R ShepheardSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Ozlem YildizBlizard Institute, Queen Mary University of London, London, UK.
Emily FenebergNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0001-5905-3826
Lucy FarrimondNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Thanuja DharmadasaNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Pamela GrayNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Evan C EdmondNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Jakub ScaberNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-0146-1821
Delia GagliardiNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Janine KirbySheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-7468-5917
Thomas M JenkinsSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Pietro FrattaBlizard Institute, Queen Mary University of London, London, UK.
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Sanjay G ManoharNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-0735-4349
Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0001-5490-1697
Andrea MalaspinaBlizard Institute, Queen Mary University of London, London, UK.
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0003-0267-3180
University of Oxford · GBUniversity of Sheffield · GBQueen Mary University of London · GB

Funding

Medical Research Council MR/M008606/1Medical Research Council MR/S004920/1Medical Research Council MR/S006508/1Medical Research Council MR/T006927/1Motor Neurone Disease Association FRATTA/JAN15/946-795Motor Neurone Disease Association NECTAR/OCT15/974-797Motor Neurone Disease Association TURNER/OCT15/972-797Motor Neurone Disease Association TURNER/OCT18/989-797
6 · The paper itself

Abstract

The routine clinical integration of individualized objective markers of disease activity in those diagnosed with the neurodegenerative disorder amyotrophic lateral sclerosis is a key requirement for therapeutic development. A large, multicentre, clinic-based, longitudinal cohort was used to systematically appraise the leading candidate biofluid biomarkers in the stratification and potential therapeutic assessment of those with amyotrophic lateral sclerosis. Incident patients diagnosed with amyotrophic lateral sclerosis (

Indexed as

amyotrophic lateral sclerosisbiomarkermotor neuron diseaseneurofilamenttrial

Identifiers

PMID35224491
PMCPMC8870425
OpenAlexW4210521274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.